<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Delbaldo C</dc:creator>
  <dc:creator>Chen M</dc:creator>
  <dc:creator>Friedli A</dc:creator>
  <dc:creator>Prins C</dc:creator>
  <dc:creator>Desmeules J</dc:creator>
  <dc:creator>Saurat JH</dc:creator>
  <dc:creator>Woodley DT</dc:creator>
  <dc:creator>Borradori L</dc:creator>
  <dc:date>2002</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">We describe a 73-year-old patient who had a subepidermal bullous eruption develop after a course of antibiotics, including vancomycin. The patient had deposits of IgA and IgG in the cutaneous basement membrane zone that were located on the dermal side of 1 M NaCl-treated autologous skin. By an enzyme-linked immunosorbent assay, the patient was found to have circulating IgG antibodies directed against type VII collagen, the target antigen of epidermolysis bullosa acquisita. Our observation expands the spectrum of immune-mediated subepidermal bullous skin eruptions precipitated by drugs and lends support to the idea that a subset of these cases represents an unusual variant of drug-triggered epidermolysis bullosa acquisita.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/95602</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1067/mjd.2002.107774</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/12004302</dc:relation>
  <dc:source>Journal of the American Academy of Dermatology. - 2002</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Adenocarcinoma</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Autoantibodies</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Biopsy, Needle</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Collagen</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Enzyme-Linked Immunosorbent Assay</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Epidermolysis Bullosa Acquisita</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Fluorescent Antibody Technique, Direct</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Follow-Up Studies</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Gentamicins</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Infusions, Intravenous</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Pancreatic Neoplasms</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Surgical Wound Infection</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Vancomycin</dc:subject>
  <dc:title xmlns:ns16="xml" ns16:lang="en">Drug-induced epidermolysis bullosa acquisita with antibodies to type VII collagen.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
